News Channel Island Firm Secures Britain’s First High-THC Commercial Cultivation...

Channel Island Firm Secures Britain’s First High-THC Commercial Cultivation Licence For Over 20 Years

-

CHANNEL islands company Northern Leaf has successfully secured a medical cannabis cultivation licence to produce medicines for the UK and European markets.

The Jersey Government, under the guidance of the UK Home Office, has issued Northern the first British high-THC (Tetrahydrocannabinol) commercial cultivation licence since 1998.

The multimillion pound development will see Northern Leaf start commercial cannabis cultivation in the next few weeks with the aim of supplying product to the European market. 

This will be seen as a major breakthrough for the UK medical cannabis community and comes almost two decades after the first commercial high-THC medical cannabis licence was issued to GW Pharmaceuticals in 1998.

The Global Market Is Under-Supplied

Backed by London-based venture capital firm Chrystal Capital Partners Northern has acquired 75,000 sq ft of greenhouses – equivalent to the size of a football pitch.

Campbell Dunlop, chief executive of Northern Leaf, told the Financial Times: “Demand is increasing globally and the market is currently undersupplied.”

Tristan Gervais, Head of Chrystal Capital Cannabis Advisory, told BusinessCann: “We are delighted to have advised Northern Leaf on securing the first full commercial medical cannabis licence that has been awarded in the British Isles since GW Pharmaceuticals 22 years ago. 

“This is a significant milestone for Northern Leaf and a big step towards its goal of becoming a leading supplier of EU-GMP grade medical cannabis to the rapidly growing European markets, forecast to be worth $3.9bn per annum by 2025.”

Trail Was Blazed By GW Pharmaceuticals

The cannabis plants will be processed and cannabinoids extracted at the Jersey facility which will also produce pharmaceutical-grade flowers and oils for the wholesale market, or to be processed into Northern’s own brands. It is also exploring ways to enter the UK market through the ‘specials’ medicine’ route.

Northern says the award of the licence is a strong endorsement, at Government level, of the quality of the company’s pharmaceutical-grade operations and management team.  

Speaking to BusinessCann Kingsley Wilson, Co-Founder of Chrystal Capital Partners spoke of its £3m investment in the company to date.

“We have helped Northern Leaf become established by acquiring greenhouses in Jersey and helping in the development of the management team, as well as helping secure its high-THC licence and bringing in off-take partners for its products.

“We have raised £3m so far for the business and will be helping to raise a further £5m.”

The development will see Northern become the UK’s second domestic medical cannabis producer following trailblazer GW Pharmaceuticals.

GW is one of the world’s leading medical cannabis companies with its home-grown cannabis going into its licensed drugs Sativex and Epidyolex. Its first cultivation facility was built over 20 years ago.

Its research operations are based in Kent and its growing facilities are owned and managed by British Sugar in Wissington, Norfolk. They consist almost 2m sq ft of growing space – equivalent to 34 football pitches.

Chrystal’s cannabis practice is the only dedicated cannabis corporate finance advisory team in Europe. This is Chrystal’s 14th cannabis advisory deal in the last four years. It has raised and advised on over $400m of public and private transactions in the cannabis sector across North America, Latin America and Europe. 

Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

Children’s Dutch Epilepsy Cannabis Medicines Will Be Made In The UK To Overcome Import Impasse

A PERMANENT solution to the import impasse on children’s epilepsy cannabis medication has emerged with the Dutch manufacturer set...

‘The Dutch Bedrocan Medicine Is The Only Viable Option For Treating Many Children’s Epilepsy’

Prof Mike Barnes, one of the UK's leading cannabis clinicians responds to suggestions that the medicines for UK children...

Amazon Enters CBD Retail Market – But Only In One Country

GLOBAL on-line retail giant Amazon is dipping its toes into the CBD market with the first ever products now...

The UK Medical Cannabis Industry Can – And Does – Provide Epilepsy Medicines For Children In Post-Brexit Britain

Pierre Van Weperen of Grow Pharma on the post-Brexit issue surrounding the import of epilepsy cannabis medicines into the...

Dozens of CBD Brands In A State of ‘Absolute Panic’ With UK Novel Food Deadline Weeks Away

THE New Year has brought a realisation that the Novel Food deadline is less than three months away leading...

Work Gets Underway On Scotland’s First Medical Cannabis Cultivation and Production Facility

SCOTLAND’S first home-grown cannabis medicines could be in UK patients’ hands in early 2022 after work started on a...

Must read

Children’s Dutch Epilepsy Cannabis Medicines Will Be Made In The UK To Overcome Import Impasse

A PERMANENT solution to the import impasse on children’s...

You might also likeRELATED
Recommended to you